Antiobesity pharmacotherapy in the management of type 2 diabetes (Q33883725)

29 July 2017

1 reference

title

Antiobesity pharmacotherapy in the management of type 2 diabetes (English)

1 reference

29 July 2017

0 references

1 reference

Scheen AJ

1

1 reference

29 July 2017

Lefèbvre PJ

series ordinal

2

1 reference

29 July 2017

publication date

1 March 2000

1 reference

Diabetes - Metabolism: Research and Reviews

29 July 2017

published in

1 reference

29 July 2017

volume

16

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

114-124

1 reference

Promoting weight loss in type II diabetes

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

The Prevention and Treatment of Obesity: Application to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Oral antidiabetic agents. A guide to selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Therapy for obesity--today and tomorrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Drug treatment of obesity in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Current concepts in the pharmacological management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Fenfluramine therapy in non-insulin-dependent diabetic patients: effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Fenfluramine increases insulin action in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

International trial of long-term dexfenfluramine in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Clinical studies with dexfenfluramine: from past to future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

The Comparison of Four Weight Reduction Strategies Aimed at Overweight Diabetic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Combined drug treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Pharmacologic induction of weight loss to treat type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Fluoxetine in the treatment of obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

A Study of Fluoxetine in Obese Elderly Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Effect of gamma-irradiation on mouse pancreatic islet-allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Sibutramine. A review of its contribution to the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Hypoglycemia Overrides Amylin-Mediated Regulation of Gastric Emptying in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Antiobesity and antidiabetic beta-agonists: lessons learned and questions to be answered

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Tumor necrosis factor alpha: a key component of the obesity-diabetes link

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Effect of metformin on food intake in obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Benfluorex and blood glucose control in non insulin-dependent diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

The role of amylin in the physiology of glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

21 January 2018

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Clomipramine, Fluoxetine, and Glucose Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200003%2F04%2916%3A2%3C114%3A%3AAID-DMRR97%3E3.0.CO%3B2-O

10.1002/(SICI)1520-7560(200003/04)16:2<114::AID-DMRR97>3.0.CO;2-O

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference